Maria Elena Nizzoli

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study

Rexhep Durmo, Benedetta Donati, Louis Rebaud et al. · Hematological Oncology · 2022 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network

Sara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi et al. · Hematological Oncology · 2019 · 36 citations

Medicine, Hematology, Infectious Diseases +12

Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study

Livio Pagano, Marianna Criscuolo, Alessandro Broccoli et al. · Blood Cancer Journal · 2022 · 31 citations · Full text

Medicine, Hematology, Pharmacology +11

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

Lisa Argnani, Alessandro Broccoli, Cinzia Pellegrini et al. · HemaSphere · 2022 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A risk‐stratification model based on the initial concentration of the serum monoclonal protein and <i><scp>MYD</scp>88</i> mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders

Marzia Varettoni, Silvia Zibellini, Emanuela Boveri et al. · British Journal of Haematology · 2019 · 20 citations · Full text

Life Sciences, Immunology, Pathology +8